Omnicomm Systems Inc., Introduces New TrialMaster V.4.0 at DIA's 42nd Annual Meeting
TrialMaster V.4.0. is a flexible, painless, and affordable eClinical Solution.
Philadelphia, June 18–20, Booth # 1144- OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, announced today the launch of TrialMaster™ Version 4.0 eClinical trial solution.
TrialMaster™ Version 4.0 includes:
- eData Capture functionality
- Data Management functionality
- Trial Management functionality
- Easy Trial Build capability
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Cardiff Reports 49% Response Rate With Onvansertib in RAS-Mutated Colorectal Cancer
July 31st 2025In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in first-line RAS-mutated metastatic colorectal cancer, with a favorable safety profile and dose-dependent efficacy across endpoints.
ACT Brief Episode 1: Placebos, Politics, and the Ethics of Vaccine Trials
July 31st 2025In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials in the US, why experts warn it violates core ethical standards, and how these proposals could jeopardize both participant safety and future innovation.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL
July 29th 2025The application is backed by Phase III AMPLIFY trial results showing the oral combination significantly improved progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
